Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals

Drug Profile

Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals

Alternative Names: Anti-Stx monoclonal antibodies; c-Stx1; c-Stx1/c-Stx2; c-Stx2; caStx1; caStx1/caStx2; caStx2; Shigamab; Shigamabs

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sunol Molecular Corporation; Uniformed Services University of the Health Sciences
  • Developer BELLUS Health; Taro Pharmaceuticals Inc
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Escherichia coli infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haemolytic uraemic syndrome
  • Discontinued Shiga-toxigenic Escherichia coli infections

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in USA (IV, Infusion)
  • 16 Mar 2017 Thallion Pharmaceuticals including anti-Shiga toxin monoclonal antibodies acquired by Taro Pharmaceuticals from Bellus Health
  • 12 Nov 2015 BELLUS Health plans a phase II trial for Haemolytic uraemic syndrome (In children)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top